Great heterogeneity in survival exists for patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL).SkiptoMainContentAdvertisementCloseBloodBloodAdvancesHematologyASH-SAPASHClinicalNewsTheHematologistInternationalBloodChineseEditionBloodJapaneseEditionBloodItalianEditionBloodLatinAmericaEditionBloodSpanishEditionASHASHHomeResearchEducationAdvocacyMeetingsPublicationsASHStoreCartUserToolsCartSignInSearchnavsearchsearchinputSearchinputautosuggestsearchfilterAllContentAllJournalsBloodSearchToggleMenuMenuIssuesCurrentIssueAllIssuesFirsteditionAbstracts2020AnnualMeeting2020LateBreaking2019AnnualMeeting2019LateBreaking2018AnnualMeetingAllMeetingAbstractsCollectionsCollectionsSpecialCollectionsMultimediaAlertsAuthorCenterSubmitAuthorGuideStyleGuideWhySubmittoBlood?AboutAboutBloodEditorialBoardandStaffSubscriptionsPublicAccessCopyrightAlertsBloodClassifiedsSkipNavDestinationContentMenuCloseKeyPointsAbstractIntroductionMethodsResultsDiscussionAcknowledgmentsAuthorshipREFERENCESArticleNavigationCLINICALTRIALSANDOBSERVATIONS|June4,2020InternationalprognosticindicesindiffuselargeB-celllymphoma:acomparisonofIPI,R-IPI,andNCCN-IPIClinicalTrials&ObservationsAmyS.Ruppert,AmyS.Ruppert1DepartmentofInternalMedicine,TheOhioStateUniversity,Columbus,OH;Searchforotherworksbythisauthoron:ThisSitePubMedGoogleScholarJesseG.Dixon,JesseG.Dixon2DepartmentofHealthScienceResearch,MayoClinic,Rochester,MN;Searchforotherworksbythisauthoron:ThisSitePubMedGoogleScholarGillesSalles,GillesSalles3Hematology,CentreHospitalierLyon-Sud,HospicesCivilsdeLyon,UniversityofLyon,Pierre-Benite,France;  https://orcid.org/0000-0002-9541-8666Searchforotherworksbythisauthoron:ThisSitePubMedGoogleScholarAnnaWall,AnnaWall2DepartmentofHealthScienceResearch,MayoClinic,Rochester,MN;Searchforotherworksbythisauthoron:ThisSitePubMedGoogleScholarDavidCunningham,DavidCunningham4DepartmentofMedicine,RoyalMarsdenHospital,Surrey,UnitedKingdom;  https://orcid.org/0000-0001-5158-1069Searchforotherworksbythisauthoron:ThisSi

The authors evaluated clinical predictors of outcomes in 1234 patients with diffuse large B-cell lymphoma (DLBCL) at first relapse or ...centerofexcellencealarmbookmarkcalendarcheck-clipboardclockwisecommentcompass-navigatecompasscounterclockwisedeletedownload-bookeducation-historyemailget-helpgizmo-flaghelp-iconjournalleftlinklocklog-inlog-outnavigate-downnavigate-leftnavigate-rightnavigate-upnotifications-disabledopen-bookpersonplay-videoplayrefreshrightrightwardsearchsettingsshare-2starthumbs-upsharecheck-box3linesicon-social-facebookicon-social-instagramicon-social-linkedinicon-social-twittericon-social-youtubeprinter-2insert-boxeshelp-iconlocationpluspaperclipdownloadclockwisecheck-circleexclamationWehavedetectedthatyouareusinganAdBlocker.PracticeUpdateisfreetoendusersbutwerelyonadvertisingtofundoursite.PleaseconsidersupportingPracticeUpdatebywhitelistingusinyouradblocker.Wehavesentamessagetotheemailaddressyouhaveprovided,.Ifthisemailisnotcorrect,pleaseupdateyoursettingswithyourcorrectaddress.Theemailaddressyouprovidedduringregistration,,doesnotappeartobevalid.PleaseupdateyoursettingswithavalidaddressbeforetocontinueusingPracticeUpdate.PleaseprovideyourAHPRANumbertoensurethatyouaregiventhecorrectlevelofaccesstooursite.CloseBackSigninJoinnowFollowuson:SearchPracticeUpdateCancelSearch×SignintoPracticeUpdateOnlyregisteredmembershavefullaccesstoPracticeUpdatecontent.SigninNotamember?JoinforfreeAdditionalInfoArticleCitationAmericanJournalofHematologyRelapsed/RefractoryInternationalPrognosticIndex(R/R-IPI):AnInternationalPrognosticCalculatorforRelapsed/RefractoryDiffuseLargeB-CellLymphomaAm.J.Hematol2021Mar04;[EPubAheadofPrint],MJMaurer,LHJakobsen,RMwangi,NSchmitz,UFarooq,CRFlowers,PdeNullyBrown,CAThompson,HFrederiksen,DCunningham,JJørgensen,VPoeschel,GNowakowski,JFSeymour,FMerli,CHaioun,HGhesquieres,MZiepert,HTilly,GSalles,QShi,TCEl-Galaly,TMHabermannFromMEDLINE®/PubMed®,adatabaseoftheU.S.NationalLibraryofMedicine.FurtherReadingfeaturedTherapeutic-DoseHeparinforThro

Here, we develop and validate a clinical risk calculator (IPI24) for ... Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of ...NCBISkiptomaincontentSkiptonavigationResourcesHowToAboutNCBIAccesskeysMyNCBISignintoNCBISignOutTryoutPMCLabsandtelluswhatyouthink.LearnMore.JournalListHHSAuthorManuscriptsPMC4801345AmJHematol.Authormanuscript;availableinPMC2017Feb1.Publishedinfinaleditedformas:AmJHematol.2016Feb;91(2):179–184.Publishedonline2015Nov26.doi: 10.1002/ajh.24223PMCID:PMC4801345NIHMSID:NIHMS767894PMID:26492520Personalizedriskpredictionforevent-freesurvivalat24monthsinpatientswithdiffuselargeB-celllymphomaMatthewJ.Maurer,1,*Jean-PhilippeJais,2HervéGhesquières,3,4ThomasE.Witzig,5FangxinHong,6CorinneHaioun,7CarrieA.Thompson,5CatherineThieblemont,8IvanaN.Micallef,5LuisF.Porrata,5VincentRibrag,9GregorzS.Nowakowski,5OlivierCasanovas,10SergeBologna,11FranckMorschhauser,12VickiA.Morrison,13,14BruceA.Peterson,13WilliamR.Macon,15ChristianeCopie-Bergman,16AndrewL.Feldman,15SergeiI.Syrbu,17PaulJ.Kurtin,15RandyD.Gascoyne,18HailunLi,6CristineAllmer,1BradS.Kahl,19StephenM.Ansell,5SusanL.Slager,1BrianK.Link,17GillesSalles,4,20ThomasM.Habermann,5HervéTilly,21andJamesR.Cerhan1MatthewJ.Maurer1DepartmentofHealthSciencesResearch,MayoClinic,Rochester,MinnesotaFindarticlesbyMatthewJ.MaurerJean-PhilippeJais2DepartmentofBiostatistics,NeckerHospital,INSERMUMRS872,AP-HP,Paris,FranceFindarticlesbyJean-PhilippeJaisHervéGhesquières3DepartmentofMedicalOncology,CentreLéonBérard,Lyon,France4CentreNationalDeLaRechercheScientifique(CNRS),UniteMixteDeRecherche(UMR),UniversitéClaudeBernard,Lyon,FranceFindarticlesbyHervéGhesquièresThomasE.Witzig5DivisionofHematology,MayoClinic,Rochester,MinnesotaFindarticlesbyThomasE.WitzigFangxinHong6DepartmentofBiostatistics&ComputationalBiology,HarvardT.H.Chan,Boston,MassachusettsFindarticlesbyFangxinHongCorinneHaioun7LymphoidMalignanciesUnit,HenriMondorHospital,UniversitéParis-Est,Créteil,FranceFindarticlesbyCorinneHaiounCarrieA.Thompson5Divisionof

Disease progression after frontline therapy for Diffuse large B-cell lymphoma (DLBCL) is a clinically significant event.Clipboard,SearchHistory,andseveralotheradvancedfeaturesaretemporarilyunavailable.SkiptomainpagecontentCOVID-19InformationPublichealthinformation(CDC)Researchinformation(NIH)SARS-CoV-2data(NCBI)Preventionandtreatmentinformation(HHS)Español AccesskeysNCBIHomepageMyNCBIHomepageMainContentMainNavigationSearch:SearchAdvancedClipboardUserGuideSaveEmailSendtoClipboardMyBibliographyCollectionsCitationmanagerDisplayoptionsDisplayoptionsFormatAbstractPubMedPMIDSavecitationtofileFormat:Summary(text)PubMedPMIDAbstract(text)CSVCreatefileCancelEmailcitationSubject:1selecteditem:33661547-PubMedTo:Format:SummarySummary(text)AbstractAbstract(text)MeSHandotherdataSendemailCancelAddtoCollectionsCreateanewcollectionAddtoanexistingcollectionNameyourcollection:Namemustbelessthan100charactersChooseacollection:UnabletoloadyourcollectionduetoanerrorPleasetryagainAddCancelAddtoMyBibliographyMyBibliographyUnabletoloadyourdelegatesduetoanerrorPleasetryagainAddCancelYoursavedsearchNameofsavedsearch:Searchterms:TestsearchtermsWouldyoulikeemailupdatesofnewsearchresults?SavedSearchAlertRadioButtonsYesNoEmail:(change)Frequency:MonthlyWeeklyDailyWhichday?ThefirstSundayThefirstMondayThefirstTuesdayThefirstWednesdayThefirstThursdayThefirstFridayThefirstSaturdayThefirstdayThefirstweekdayWhichday?SundayMondayTuesdayWednesdayThursdayFridaySaturdayReportformat:SummarySummary(text)AbstractAbstract(text)PubMedSendatmost:1item5items10items20items50items100items200itemsSendevenwhentherearen'tanynewresultsOptionaltextinemail:SaveCancelCreateafileforexternalcitationmanagementsoftwareCreatefileCancelYourRSSFeedNameofRSSFeed:Numberofitemsdisplayed:510152050100CreateRSSCancelRSSLinkCopyFulltextlinksWileyFulltextlinksActionsCiteFavoritesDisplayoptionsDisplayoptionsFormatAbstractPubMedPMIDSharePermalinkCopyPagenavigationTitle&authorsAbstractSimilararticlesReferencesPublicationtypesMeSHtermsRelatedi

What is DLBCL? · Signs and symptoms of DLBCL · Diffuse large B-cell lymphoma staging · How to calculate DLBCL prognosis with the IPI score?OmniCalculatorlogoWe’rehiring!EmbedShareviaDiffuseLargeB-cellLymphomaPrognosisCalculatorByŁucjaZaborowska,PhDcandidateLastupdated:Mar03,2021Tableofcontents:WhatisDLBCL?SignsandsymptomsofDLBCLDiffuselargeB-celllymphomastagingHowtocalculateDLBCLprognosiswiththeIPIscore?ThediffuselargeB-celllymphomaprognosiscalculatorestimatestheoverall&progression-freesurvivalwiththeuseoftherevisedIPIscoreforlymphoma.OurtoolservesasasimpleDLBCLprognosiscalculator–readontofindoutmoreaboutthediffuselargeB-celllymphomastaging,signsandsymptoms.🌡️WhatisDLBCL?DLBCLstandsforthediffuselargeB-celllymphoma.WhenwethinkaboutDLBCL,weusuallyconsideritaveryaggressiveneoplasmthatcaneasilyspreadtodifferentpartsofthebodyandcausesymptomsconnectedtorapidlygrowingcancermassescells.💡Lymphomaitselfisakindofbloodcancerthatdevelopsfromwhitebloodcells,calledlymphocytes.Lymphomasaredifferentfromleukemia(anothertypeofbloodcancer)becausetheymayformvisible,solidtumors;theirtypicalplaceofgrowtharelymphnodes,spleen,thymus.DLBCLisusuallydetectedamongolderpeople–it'sarelativelycommonlymphoma.Themostadvancedtypeofthedisease,DLBCLstage4,carries65%chanceofsurvival.🔎Rememberthateverysinglediseaseisdifferent–takealookatourdiffuselargeB-celllymphomaprognosiscalculatortofindoutprobableprognosismeasuredforyourspecificcircumstances.💉Bloodanditsneoplasmarebothprettydifficultsubjects–wouldyouliketofindoutmoreaboutit?MantlecelllymphomaHematocritandhemoglobinBloodtypeReticulocyteSignsandsymptomsofDLBCLLymphomasmaygounnoticedforalongerperiodoftime,uptothepointwhentheycausesevereandsuddencomplications.However,patientsusuallyexperienceso-calledB-symptoms,whichcanbeeasilyoverlooked:Fatigue😴Nightsweats💧Weightloss,withoutanyapparentreason,exerciseoraspecialdiet⚖️Unexplainedfever🌡️Suddeneventsthatrequiremedicalattentionconnectedtothelymphomainclude:Superiorvenacavasyndrome–swellingandreddeningoftheupp

Predicts overall and progression-free survival in DLBCL based on risk factors. ... Note: IPI results are included for historical comparisons only. Use in CD20+ ...Thisisanunprecedentedtime.Itisthededicationofhealthcareworkersthatwillleadusthroughthiscrisis.Thankyouforeverythingyoudo.COVID-19ResourceCenterCalcFunctionCalcsthathelppredictprobabilityofadiseaseDiagnosisSubcategoryof'Diagnosis'designedtobeverysensitiveRuleOutDiseaseisdiagnosed:prognosticatetoguidetreatmentPrognosisNumericalinputsandoutputsFormulaMedtreatmentandmoreTreatmentSuggestedprotocolsAlgorithmDiseaseSelect...SpecialtySelect...ChiefComplaintSelect...OrganSystemSelect...PatentPendingLogInEmailAddressPasswordShowForgotyourpassword?LogInOrcreateanewaccount(it'sfree)ForgotPassword?EmailAddressEnteryouremailaddressandwe'llsendyoualinktoresetyourpassword.GetNewPasswordSignInRequiredTosavefavorites,youmustlogin.Creatinganaccountisfree,easy,andtakesabout60seconds.LogInCreateAccountAttentionCOACHSTUDYparticipants:Theprincipalinvestigatorsofthestudyrequestthatyouusetheofficialversionofthemodifiedscorehere.InternationalPrognosticIndexforDiffuseLargeB-cellLymphoma(IPIandR-IPI)Predictsoverallandprogression-freesurvivalinDLBCLbasedonriskfactors.INSTRUCTIONSNote:IPIresultsareincludedforhistoricalcomparisonsonly.UseinCD20+DLBCLpatients.DonotuseinpatientswithHIV,secondarymalignancies,lowgradelymphoproliferativedisorders,orcomorbiditiesprecludingcurativetherapyattempt.WhentoUsePearls/PitfallsWhyUseUseinCD20+DLBCLpatients.DonotuseinpatientswithHIV,secondarymalignancies,lowgradelymphoproliferativedisorders,orcomorbiditiesprecludingcurativetherapyattempt.TheInternationalPrognosticIndexforDiffuseLargeB-cellLymphoma(IPIandR-IPI)estimates4-yearprogression-freesurvivaland4-yearoverallsurvivalforpatientswithdiffuselargeB-cellnon-Hodgkin’slymphoma(DLBCL).TheR-IPIprovidesgreaterdiscriminationamongstDLBCLpatientswithdifferingsurvivalbasedoneasilyobtainedfactors.Doesnotidentifyanyriskgroupwith4-yearsurvival<50%;hence,othermolec

Determine prognosis in diffuse large B-cell lymphoma. ... CalculatorReferences/About. 1.Age? 2.Performance? 3.LDH? 4.Extranodal Sites? 5.Stage? Created by ...ForYouNews&PerspectiveDrugs&DiseasesCME&EducationAcademyVideoDecisionPointEdition:ENGLISHDEUTSCHESPAÑOLFRANÇAISPORTUGUÊSLogInSignUpIt'sFree!Edition:ENGLISHDEUTSCHESPAÑOLFRANÇAISPORTUGUÊSRegisterLogInNoResultsNoResultsForYouNews&PerspectiveDrugs&DiseasesCME&EducationAcademyVideoDecisionPointclosePleaseconfirmthatyouwouldliketologoutofMedscape.Ifyoulogout,youwillberequiredtoenteryourusernameandpasswordthenexttimeyouvisit.LogoutCancelDrugs&Diseases>CalculatorsDiffuseLargeB-CellLymphomaPrognosis(R-IPI)DetermineprognosisindiffuselargeB-celllymphomaTheglobalunitselectoronlyaffectsunansweredquestionsSiUSCalculatorReferences/About1.Age?2.Performance?3.LDH?4.ExtranodalSites?5.Stage?1.Age?≤60Years>60YearsNextQuestion0/5completedStartAboutthisCalculatorTheoriginalInternationalPrognosticIndex(IPI)wasdevelopedandvalidatedpriortotheadditionofrituximabtocurativeanthracycline-basedchemotherapy.ClinicaltrialshaveconfirmedthatrituximabimprovesthesurvivalofindividualswithdiffuselargeB-celllymphoma.TherevisedInternationalPrognosticIndex(R-IPI)wasdevelopedtopredicttheoutcomeofindividualsreceivingrituximabwithchemotherapy.Thescoreisabletodifferentiatepatientsintothreegroups(verygood,good,poor),allofwhohavesurvival>50%inthenewera.ReferencesTheoriginalIPIwasdevelopedbyShippetal.Apredictivemodelforaggressivenon-Hodgkin'slymphoma.NewEnglandJournalofMedicine1993September30,329(14):987-94Thenewerprognosticindexwasrevised/developedbySehnetal.TherevisedInternationalPrognosticIndex(R-IPI)isabetterpredictorofoutcomethanthestandardIPIforpatientswithdiffuselargeB-celllymphomatreatedwithR-CHOP.Blood2007March1,109(5):1857-61RelatedCalculatorsNorelatedcalculatorsfoundforDiffuseLargeB-CellLymphomaPrognosis(R-IPI)RelatedArticlesNorelatedarticlesfoundforDiffuseLargeB-CellLymphomaPrognosis(R-IPI)LegalNoticesandDisclaimer©2020QxMDSoftwareInc.,allrights